{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:51:45Z","timestamp":1776729105859,"version":"3.51.2"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.canlet.2010.04.029","type":"journal-article","created":{"date-parts":[[2010,5,25]],"date-time":"2010-05-25T08:21:40Z","timestamp":1274775700000},"page":"91-100","source":"Crossref","is-referenced-by-count":23,"title":["HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis"],"prefix":"10.1016","volume":"297","author":[{"given":"J.C.","family":"Morales","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Ruiz-Maga\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Carranza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Ortiz-Ferr\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ruiz-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2010.04.029_bib1","doi-asserted-by":"crossref","first-page":"25417","DOI":"10.1074\/jbc.272.41.25417","article-title":"Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL","volume":"272","author":"MacFarlane","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2010.04.029_bib2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.276.5309.111","article-title":"The receptor for the cytotoxic ligand TRAIL","volume":"276","author":"Pan","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.canlet.2010.04.029_bib3","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1093\/emboj\/16.17.5386","article-title":"TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL","volume":"16","author":"Walczak","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2010.04.029_bib4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0092-8674(95)90071-3","article-title":"FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis","volume":"81","author":"Chinnaiyan","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2010.04.029_bib5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1074-7613(00)80211-3","article-title":"FADD\/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2","volume":"12","author":"Sprick","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2010.04.029_bib6","doi-asserted-by":"crossref","first-page":"6809","DOI":"10.1038\/sj.onc.1205853","article-title":"Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia","volume":"21","author":"MacFarlane","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2010.04.029_bib7","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/BF03402036","article-title":"Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis","volume":"8","author":"Siegmund","year":"2002","journal-title":"Mol. Med."},{"key":"10.1016\/j.canlet.2010.04.029_bib8","doi-asserted-by":"crossref","first-page":"7128","DOI":"10.1038\/sj.onc.1204887","article-title":"The differential sensitivity of Bcl-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bcl-2 protein levels","volume":"20","author":"Ruiz de Almodovar","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2010.04.029_bib9","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/0008-5472.CAN-04-0046","article-title":"X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells","volume":"64","author":"Cummins","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2010.04.029_bib10","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1126\/science.1098231","article-title":"A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death","volume":"305","author":"Li","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.canlet.2010.04.029_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjc.6603844","article-title":"Histone modifications as markers of cancer prognosis: a cellular view","volume":"97","author":"Kurdistani","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2010.04.029_bib12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00001622-200111000-00010","article-title":"Histone deacetylase inhibitors as new cancer drugs","volume":"13","author":"Marks","year":"2001","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.canlet.2010.04.029_bib13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ctrv.2004.04.006","article-title":"Histone deacetylase inhibitors \u2013 a new tool to treat cancer","volume":"30","author":"Somech","year":"2004","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.canlet.2010.04.029_bib14","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2174\/138920007780655397","article-title":"Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application","volume":"8","author":"Santini","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.canlet.2010.04.029_bib15","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.lfs.2008.03.004","article-title":"The use of diversity profiling to characterize chemical modulators of the histone deacetylases","volume":"82","author":"Blackwell","year":"2008","journal-title":"Life Sci."},{"key":"10.1016\/j.canlet.2010.04.029_bib16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1042\/BJ20070779","article-title":"Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors","volume":"409","author":"Khan","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.canlet.2010.04.029_bib17","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1073\/pnas.0500369102","article-title":"Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors","volume":"102","author":"Peart","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2010.04.029_bib18","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1593\/neo.04655","article-title":"Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma","volume":"7","author":"Fandy","year":"2005","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2010.04.029_bib19","first-page":"1125","article-title":"Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways","volume":"16","author":"Shankar","year":"2005","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.canlet.2010.04.029_bib20","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1038\/sj.onc.1208585","article-title":"HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma","volume":"24","author":"Singh","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2010.04.029_bib21","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0006-2952(03)00509-4","article-title":"The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis","volume":"66","author":"Zhang","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2010.04.029_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nm1160","article-title":"Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway","volume":"11","author":"Insinga","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2010.04.029_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nm1161","article-title":"Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells","volume":"11","author":"Nebbioso","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2010.04.029_bib24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/jcb.20532","article-title":"Prospects: histone deacetylase inhibitors","volume":"96","author":"Dokmanovic","year":"2005","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.canlet.2010.04.029_bib25","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1038\/sj.cdd.4401535","article-title":"Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies","volume":"11","author":"Inoue","year":"2004","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2010.04.029_bib26","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/sj.cgt.7700939","article-title":"Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors","volume":"13","author":"VanOosten","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.canlet.2010.04.029_bib27","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.molimm.2006.12.015","article-title":"Regulation of the resistance to TRAIL-induced apoptosis in human primary T lymphocytes: role of NF-kappaB inhibition","volume":"44","author":"Morales","year":"2007","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.canlet.2010.04.029_bib28","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1006\/abio.1994.1184","article-title":"A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry","volume":"218","author":"Gong","year":"1994","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.canlet.2010.04.029_bib29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/cyto.a.20151","article-title":"New method to detect histone acetylation levels by flow cytometry","volume":"66","author":"Ronzoni","year":"2005","journal-title":"Cytometry A"},{"key":"10.1016\/j.canlet.2010.04.029_bib30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/sj.cdd.4400490","article-title":"P53-mediated up-regulation of CD95 is not involved in genotoxic drug-induced apoptosis of human breast tumor cells","volume":"6","author":"Ruiz-Ruiz","year":"1999","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2010.04.029_bib31","first-page":"5018","article-title":"Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells","volume":"9","author":"Cheong","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2010.04.029_bib32","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.1038\/sj.onc.1207830","article-title":"Histone deacetylase inhibitors upregulate death receptor 5\/TRAIL-R2 and sensitize apoptosis induced by TRAIL\/APO2-L in human malignant tumor cells","volume":"23","author":"Nakata","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2010.04.029_bib33","first-page":"1273","article-title":"Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells","volume":"2","author":"Rosato","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2010.04.029_bib34","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/sj.onc.1208191","article-title":"Type I and type II reactions in TRAIL-induced apoptosis \u2013 results from dose-response studies","volume":"24","author":"Rudner","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2010.04.029_bib35","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1158\/0008-5472.CAN-03-2629","article-title":"Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L\/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells","volume":"64","author":"Guo","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2010.04.029_bib36","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.yexcr.2009.02.024","article-title":"Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells","volume":"315","author":"Park","year":"2009","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.canlet.2010.04.029_bib37","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1158\/0008-5472.CAN-05-4563","article-title":"Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis","volume":"66","author":"Inoue","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2010.04.029_bib38","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1158\/1541-7786.MCR-07-0324","article-title":"Histone deacetylase inhibitors: overview and perspectives","volume":"5","author":"Dokmanovic","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2010.04.029_bib39","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","article-title":"Discovery and development of SAHA as an anticancer agent","volume":"26","author":"Marks","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2010.04.029_bib40","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.4049\/jimmunol.150.10.4338","article-title":"Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells","volume":"150","author":"Wesselborg","year":"1993","journal-title":"J. Immunol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383510002533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383510002533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T08:12:28Z","timestamp":1685607148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383510002533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0304383510002533"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2010.04.029","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}